Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers
An Open-label, Randomized, Multiple-dose, Replicated Crossover Study to Evaluate Drug-drug Interaction Following Co-administration of Tegoprazan or RAPA114 With Atorvastatin in Healthy Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
[Pharmacokinetic Assessments] : Blood concentration of atorvastatin, 2-OH atorvastatin
- Primary outcome: AUCτ, Css,max of atorvastatin
- Secondary outcome: Tss,max of atorvastatin, AUCτ, Css,max of 2-OH atorvastatin, metabolic ratio
[Sefety Assessments]
: Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male adults aged 19 to 55 years (inclusive) at the time of his consent.
- Body mass index (BMI) ≥ 19.0 and ≤ 27.0 kg/m2 at screening.
- Decides to participate voluntarily in the trial after being fully informed of and understanding the study completely, and provides the written informed consent to participate in the trial and to comply with the trial-specific requirements.
- Has the ability and willingness to participate in the entire period of clinical trial.
Exclusion Criteria:
- A subject with clinically significant disease or history of hepatobiliary, renal, gastrointestinal, cardiovascular, musculoskeletal, endocrine, respiratory, neuropsychiatry or hemato-oncologic system, etc.
- A subject with a history of hypersensitivity reactions to main constituents of or identical affiliation of the investigational products (ex, HMG-CoA reductase inhibitor, gastric acid suppressants), or have allergic diseases that require treatment.
- A subject with a history of genetic myopathy or family history.
- A subject who has participated in other clinical trials and received the investigational products within 180 days prior to the randomization.
- A subject who received any medications or foods that could significantly affect the absorption, distribution, metabolism, or excretion of an investigational product within 30 days prior to the randomization.
- A subject with history of whole blood donation within 60 days, or with blood components or received transfusion within 30 days prior to the randomization.
- A subject with continued consumption of alcohol more than 140 g per week.
- A subject with AST, ALT, or γ-GT levels exceeding 1.5 times of the upper limit of the reference range in the screening test.
- A subject with a calculated glomerular filtration rate of less than 60 mL / min / 1.73 m2 in the screening test.
- A subject with any positive result on serology tests for hepatitis B, hepatitis C, HIV or syphilis in the screening test.
- A subject with galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose malabsorption, etc.
- Male subject who don't have willing to accept medically acceptable contraceptive methods during the course of clinical trial, or who plan to provide sperm.
- A subject who is determined to be ineligible to participate in the clinical trial by the investigator for other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Atorvastatin 40 mg
Oral administration of Atorvastatin 40 mg tablet once daily for 7 days
|
Atorvastatin 40 mg
Other Names:
|
|
Experimental: Atorvastatin 40 mg + Tegoprazan 50 mg
Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days
|
Tegoprazan 50 mg tablet
Other Names:
Atorvastatin 40 mg
Other Names:
|
|
Active Comparator: Atorvastatin 40 mg + RAPA114
Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days
|
Atorvastatin 40 mg
Other Names:
RAPA114 tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUCτ of atorvastatin
Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
Area under the plasma drug concentration-time curve at steady state
|
Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
|
Css,max of atorvastatin
Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
Maximum concentration of drug in plasma of atorvastatin at steady state
|
Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tss,max of atorvastatin
Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
Time to Cmax at steady state
|
Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
|
AUCτ of 2-OH atorvastatin
Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
Area under the plasma drug concentration-time curve at steady state
|
Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
|
Css,max of 2-OH atorvastatin
Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
Maximum concentration of drug in plasma of 2-OH atorvastatin at steady state
|
Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
|
metabolic ratio
Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
AUCτ of 2-OH atorvastatin / AUCτ of atorvastatin
|
Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jung-ryul Kim, Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IN_APA_114
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.